
Adverum BiotechnologiesAlliance for Regenerative MedicineBiotechnology Company
ATIVESITE | The promise of in-vivo gene editing: ARM Studios Interview with Laura Sepp-Lorenzino
In vivo gene editing has promising potential to transform the future of medicine. How does this innovative science work? Laura Sepp-Lorenzino, Chief Scientific Officer at Intellia Therapeutics, sat down with Michael Lehmicke at ARM Studios to give an overview. #CGMesa23 #cellandgenetherapy
Source Alliance for Regenerative Medicine YouTube